Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Employer
-
Field
-
applications for the position of UM Postdoctoral Fellow in the Institute of Microelectronics / State Key Laboratory of Analog and Mixed-Signal VLSI (Website: https://ime.um.edu.mo/ ) . Applications are invited
-
research community in exploring near-analog biologic brain inspired solutions to reduce power consumption in neural networks. In this project you will be involved in a collaborative effort investigating
-
by Recovery and Resilience Plan (RRP) https://recuperarportugal.gov.pt/ and Next Generation EU European Funds, is available under the following conditions: OBJECTIVES | FUNCTIONS Formalizing analogy
-
leukemia (AML) and other solid cancers. Our work emphasizes therapeutic candidates targeting mitochondrial vulnerabilities, including nucleoside analogs, small GTPase inhibitors, natural plant extracts, and
-
of artificial intelligence (AI) there is a growing interest from the research community in exploring near-analog biologic brain inspired solutions to reduce power consumption in neural networks. In this project
-
Blindern, Oslo. Job description As a response to the power hungriness of artificial intelligence (AI) there is a growing interest from the research community in exploring near-analog biologic brain inspired
-
to allow remote configuration via PYVISA - Use the appropriate hardware setup and a PYVISA script to perform typical characterization tests for analog and mixed circuits - Create a tutorial to disseminate
-
, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS
-
Intercomparison Project (MeltMIP). MeltMIP, analogously to initMIP for model initialisation (Seroussi et al., 2019), tests the influence of melt parameterisation choices and parameter values on projections, through
-
gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral